J. Goldman & CO LP Axsome Therapeutics, Inc. Transaction History
J. Goldman & CO LP
- $3.8 Billion
- Q1 2025
A detailed history of J. Goldman & CO LP transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, J. Goldman & CO LP holds 2,296 shares of AXSM stock, worth $236,465. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,296
Previous 40,323
94.31%
Holding current value
$236,465
Previous $3.41 Million
92.17%
% of portfolio
0.01%
Previous 0.1%
Shares
15 transactions
Others Institutions Holding AXSM
# of Institutions
409Shares Held
36.6MCall Options Held
751KPut Options Held
568K-
Vanguard Group Inc Valley Forge, PA3.88MShares$399 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.3MShares$340 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY2.92MShares$301 Million5.58% of portfolio
-
Bvf Inc San Francisco, CA1.69MShares$174 Million8.66% of portfolio
-
Macquarie Group LTD Australia, C3976KShares$101 Million0.14% of portfolio
About Axsome Therapeutics, Inc.
- Ticker AXSM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,878,000
- Market Cap $4.42B
- Description
- Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...